V122I TTR cardiac amyloidosis in patients of African descent

Circulation: Heart Failure

Volumn 9, Issue 9, 2016, Pages

  Alexander, Kevin M ^a   Falk, Rodney H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiomyopathy; echocardiography; Editorials; heart failure; myocardium; primary amyloidosis

Indexed keywords

AMYLOID PROTEIN; BUCINDOLOL; PLACEBO; PREALBUMIN;

AFRICAN AMERICAN; ECHOCARDIOGRAPHY; EDITORIAL; GENOTYPE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; NEW YORK HEART ASSOCIATION CLASS; PENETRANCE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; AMYLOIDOSIS; ANIMAL; CARDIOMYOPATHY; DOG;

AMYLOIDOSIS; ANIMALS; CARDIOMYOPATHIES; DOGS; HUMANS; PREALBUMIN;

EID: 84988638034     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003489     Document Type: Editorial

References (10)

1. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015 36 2585 2594. doi: 10.1093/eurheartj/ehv338
2. Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M, Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009 158 607 614. doi: 10.1016/j.ahj.2009.08.006
3. Dungu JN, Papadopoulou SA, Wykes K, Mahmood I, Marshall J, Valencia O, Fontana M, Whelan CJ, Gillmore JD, Hawkins PN, Anderson LJ, Afro-Caribbean heart failure in the United Kingdom: cause, outcomes and ATTR V122I cardiac amyloidosis. Circ Heart Fail 2016 9 e003352. doi: 10.1161/CIRCHEARTFAILURE.116.003352
4. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD, The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015 372 21 29. doi: 10.1056/NEJMoa1404852
5. The Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001 344 1659 1667. doi: 10.1056/NEJM200105313442202
6. Buxbaum J, Jacobson DR, Tagoe C, Alexander A, Kitzman DW, Greenberg B, Thaneemit-Chen S, Lavori P, Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006 47 1724 1725. doi: 10.1016/j.jacc.2006.01.042
7. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ, Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013 2 e000098. doi: 10.1161/JAHA.113.000098
8. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L, Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008 40 232 239. doi: 10.1080/07853890701842988
9. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM, Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014 2 113 122. doi: 10.1016/j.jchf.2013.11.004
10. Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB, Evolving landscape in the management of transthyretin amyloidosis. Ann Med 2015 47 625 638. doi: 10.3109/07853890.2015.1068949